Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for Obinutuzumab IRRs in B-CLL
NCT02336048Phase 1Terminated
- Sponsor
- Roche
- Start
- Jun 2015
- Primary completion
- Sep 2018
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial in Infusion-related reactions comparing Tocilizumab + Obinutuzumab + Chlorambucil with Placebo + Obinutuzumab + Chlorambucil (2 arms). Primary endpoint: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) at 196 days. Started Jun 2015; status: terminated.
02
Drugs
tocilizumab
03
Conditions
Infusion-related reactions
Beyond the preview
Go deeper on NCT02336048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02336048.